Skip to main content

GHRP-6 vs Hexarelin

Both GHRP-6 and Hexarelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.

GHRP-6

Evidence B

Growth Hormone Releasing Peptide 6

An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.

View full GHRP-6 profile →

Hexarelin

Evidence B

Hexarelin (HEX)

The strongest GH-releasing hexapeptide and one of the few peptides with documented direct cardiac benefits in animal models. Tachyphylaxis (diminished response over time) limits long-term use.

View full Hexarelin profile →

Side-by-Side

AttributeGHRP-6Hexarelin
Evidence GradeBB
FDA StatusNot FDA-approved — research compoundNot FDA-approved — research compound (cardioprotective signals investigated)
Typical Dose100–300 mcg, 1–3 times daily (subcutaneous)100 mcg, 1–2 times daily (subcutaneous)
Clinics Indexed6441
Categoriesgrowth-hormone, appetitegrowth-hormone, recovery

Key reported benefits — GHRP-6

  • GH release
  • Appetite stimulation
  • Cytoprotection

Key reported benefits — Hexarelin

  • Strongest GH spike of GHRPs
  • Cardioprotective signals
  • Recovery

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons